Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Advanced Cancer
Metastatic Cancer
Gastric Cancer
Gastroesophageal Junction Carcinoma
Esophageal Adenocarcinoma
PDAC - Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancer (BTC)

Interventions

DRUG: TJ033721 (givastomig)
DRUG: TJ033721 (givastomig) , nivolumab, chemotherapy
DRUG: TJ033721 (givastomig), chemotherapy
DRUG: TJ033721 (givastomig), durvalumab, chemotherapy

Sponsor

I-Mab Biopharma US Limited

Collaborators

[object Object]